Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.
de Boo LW, Jóźwiak K, Ter Hoeve ND, van Diest PJ, Opdam M, Wang Y, Schmidt MK, de Jong V, Kleiterp S, Cornelissen S, Baars D, Koornstra RHT, Kerver ED, van Dalen T, Bins AD, Beeker A, van den Heiligenberg SM, de Jong PC, Bakker SD, Rietbroek RC, Konings IR, Blankenburgh R, Bijlsma RM, Imholz ALT, Stathonikos N, Vreuls W, Sanders J, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen E, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, van der Wall E, Siesling S, Salgado R, Dackus GMHE, Hauptmann M, Kok M, Linn SC. de Boo LW, et al. Among authors: bakker sd. ESMO Open. 2024 Mar;9(3):102923. doi: 10.1016/j.esmoop.2024.102923. Epub 2024 Mar 6. ESMO Open. 2024. PMID: 38452438 Free PMC article.
Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
Wensink GE, Elferink MAG, May AM, Mol L, Hamers PAH, Bakker SD, Creemers GJ, de Groot JWB, de Klerk GJ, Haberkorn BCM, Haringhuizen AW, Hoekstra R, Hunting JCB, Kerver ED, Mathijssen-van Stein D, Polée MB, Pruijt JFM, Quarles van Ufford-Mannesse P, Radema S, Rietbroek RC, Simkens LHJ, Tanis BC, Ten Bokkel Huinink D, Tjin-A-Ton MLR, Tromp-van Driel CS, Troost MM, van de Wouw AJ, van den Berkmortel FWPJ, van der Pas AJM, van der Velden AMT, van Dijk MA, van Dodewaard-de Jong JM, van Druten EB, van Voorthuizen T, Jan Veldhuis G, Verheul HMW, Vestjens HJHMJ, Vincent J, Kranenburg OW, Punt CJA, Vink GR, Roodhart JML, Koopman M. Wensink GE, et al. Among authors: bakker sd. Br J Cancer. 2021 Jan;124(2):399-406. doi: 10.1038/s41416-020-01076-0. Epub 2020 Oct 13. Br J Cancer. 2021. PMID: 33046804 Free PMC article.
Feasibility and outcomes of a goal-directed physical therapy program for patients with metastatic breast cancer.
Groen WG, Ten Tusscher MR, Verbeek R, Geleijn E, Sonke GS, Konings IR, Van der Vorst MJ, van Zweeden AA, Schrama JG, Vrijaldenhoven S, Bakker SD, Aaronson NK, Stuiver MM. Groen WG, et al. Among authors: bakker sd. Support Care Cancer. 2021 Jun;29(6):3287-3298. doi: 10.1007/s00520-020-05852-9. Epub 2020 Oct 26. Support Care Cancer. 2021. PMID: 33104921
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.
Kester L, Seinstra D, van Rossum AGJ, Vennin C, Hoogstraat M, van der Velden D, Opdam M, van Werkhoven E, Hahn K, Nederlof I, Lips EH, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker SD, Rutgers EJ, Horlings HM, Wesseling J, Voest EE, Wessels LFA, Kok M, Oosterkamp HM, van Oudenaarden A, Linn SC, van Rheenen J. Kester L, et al. Among authors: bakker sd. Clin Cancer Res. 2022 Mar 1;28(5):960-971. doi: 10.1158/1078-0432.CCR-21-1442. Clin Cancer Res. 2022. PMID: 34965952 Free PMC article.
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.
Opdam M, van der Noort V, Kleijn M, Glas A, Mandjes I, Kleiterp S, Hilbers FS, Kruger DT, Bins AD, de Jong PC, Schiphorst PPJBM, van Dalen T, Flameling B, Rietbroek RC, Beeker A, van den Heiligenberg SM, Bakker SD, Wymenga ANM, Oving IM, Bijlsma RM, van Diest PJ, Vermorken JB, van Tinteren H, Linn SC. Opdam M, et al. Among authors: bakker sd. Breast Cancer Res Treat. 2022 Jul;194(2):265-278. doi: 10.1007/s10549-022-06618-z. Epub 2022 May 19. Breast Cancer Res Treat. 2022. PMID: 35587322 Free PMC article. Clinical Trial.
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Mann RM, Sonke GS; Dutch Breast Cancer Research Group. van der Voort A, et al. Lancet Oncol. 2024 May;25(5):603-613. doi: 10.1016/S1470-2045(24)00104-9. Epub 2024 Apr 5. Lancet Oncol. 2024. PMID: 38588682 Clinical Trial.
Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial.
van der Kruijssen DEW, Elias SG, Vink GR, van Rooijen KL, 't Lam-Boer J, Mol L, Punt CJA, de Wilt JHW, Koopman M; CAIRO4 Working Group. van der Kruijssen DEW, et al. JAMA Surg. 2021 Dec 1;156(12):1093-1101. doi: 10.1001/jamasurg.2021.4992. JAMA Surg. 2021. PMID: 34613339 Free PMC article. Clinical Trial.
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
Vliek SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, Dezentje VO, Jager A, Hokken JWE, Putter H, van der Velden AWG, Hendriks MP, Bakker SD, van Riet YEA, Tjan-Heijnen VCG, Portielje JEA, Kroep JR, Nortier JWR, van de Velde CJH, Linn SC. Vliek SB, et al. Among authors: bakker sd. J Clin Oncol. 2022 Sep 1;40(25):2934-2945. doi: 10.1200/JCO.21.00311. Epub 2022 Apr 20. J Clin Oncol. 2022. PMID: 35442755 Clinical Trial.
20 results